Zai Lab Limited (HKG:9688)

Market Cap	15.74B -40.7%
Revenue (ttm)	3.55B +8.4%
Net Income	-1.40B
EPS	-12.67
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,948,650
Open	13.85
Previous Close	13.56
Day's Range	13.85 - 14.58
52-Week Range	12.31 - 32.35
Beta	0.78
Analysts	Buy
Price Target	20.95 (+45.89%)
Earnings Date	Aug 6, 2026

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 1,784
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9688

Financial Performance

In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.

Financial numbers in USD

Analyst Summary

According to 10 analysts, the average rating for 9688 stock is "Buy." The 12-month stock price target is $20.95, which is an increase of 45.89% from the latest price.

Price Target

$20.95

(45.89% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 18, 2026

Data Sources Report a data error